Logo
x

Search

Subscribe Now

Ocrevus

Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting Multiple Sclerosis at MSVirtual2020

Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting Multiple Sclerosis at MSVirtual2020

  • September 11, 2020
Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)

Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)

  • September 9, 2020
Top 20 Prescription Drugs Based on 2022 Total Revenue

    Top 20 Prescription Drugs Based on 2022 Total Revenue

    • November 21, 2023
    Genentech Reports P-III Study (OCARINA II) Results of Ocrevus for the Treatment of Multiple Sclerosis

      Genentech Reports P-III Study (OCARINA II) Results of Ocrevus for the Treatment of Multiple Sclerosis

      • October 11, 2023
      Top 20 Monoclonal Antibodies Based on 2022 Total Revenue 

        Top 20 Monoclonal Antibodies Based on 2022 Total Revenue 

        • September 26, 2023
        Top Performing Drug – Ocrevus (July Edition)

          Top Performing Drug – Ocrevus (July Edition)

          • July 26, 2023
          Roche Reports P-III Trial (OCARINA II) Results of Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis

            Roche Reports P-III Trial (OCARINA II) Results of Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis

            • July 13, 2023
            Top Performing Drugs: Proceeding the Series

              Top Performing Drugs: Proceeding the Series

              • April 25, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.